SEC Form 4/A · accession 0001127602-17-012946
Bioverativ Inc. · BIVV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Coelho Rogerio Vivaldi
Officer — EVP, Chief Global Therapeutics
Period of report
Feb 14, 2017
Accepted (ET)
Mar 27, 2017 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681689
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF1,F2 | $44.51 | Feb 14, 2017 | A | 56,615 | A | — | Feb 14, 2027 | Common Stock | 56,615 | 56,615 | D |
| Non-Qualified Stock OptionF1,F3 | $44.51 | Feb 14, 2017 | A | 113,230 | A | — | Feb 14, 2027 | Common Stock | 113,230 | 113,230 | D |
Explanation of responses
- F1The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing.
- F2This option vests in three equal annual installments beginning on February 14, 2018.
- F3This option vests in full on the third anniversary of the date of grant.